|
Recognition and Treatment of HDL-C in Mixed Dyslipidemia
|
 |
Event Overview
A low level of HDL cholesterol is common in patients with obesity, insulin resistance and mixed dyslipidemia, and is an important independent risk factor for coronary heart disease. Whether low HDL-C is causally related to CHD remains a topic of debate, but clinical intervention to raise HDL-C levels is of substantial interest. Lifestyle intervention, particularly exercise and weight loss, can help to raise HDL-C levels but is often limited. Nicotinic acid (niacin) is the best HDL-raising pharmacologic therapy currently available; while some outcome data suggest benefit, more data are needed and studies are ongoing. CETP inhibitors raise HDL-C substantially in humans, and despite the failure of torcetrapib, some CETP inhibitors are still in clinical development and have promise. Additional HDL-targeted therapies are also in development. |
Event Date
Friday, 10/30/2009 12:00 PM
|
Event Address
North Sunflower Medical Center
840 N. Oak Ave
Ruleville, MS 38771
Map |
Contact
To contact the event organizer for questions regarding this event, please click here.
|
|
|
|
|
